Advertisement
Australia markets close in 30 minutes
  • ALL ORDS

    8,119.40
    -12.70 (-0.16%)
     
  • ASX 200

    7,849.60
    -14.10 (-0.18%)
     
  • AUD/USD

    0.6661
    -0.0010 (-0.15%)
     
  • OIL

    79.22
    -0.58 (-0.73%)
     
  • GOLD

    2,419.10
    -19.40 (-0.80%)
     
  • Bitcoin AUD

    106,705.49
    +5,884.70 (+5.84%)
     
  • CMC Crypto 200

    1,523.38
    +168.96 (+12.47%)
     
  • AUD/EUR

    0.6130
    -0.0008 (-0.12%)
     
  • AUD/NZD

    1.0915
    -0.0004 (-0.03%)
     
  • NZX 50

    11,675.99
    -59.72 (-0.51%)
     
  • NASDAQ

    18,674.19
    +127.96 (+0.69%)
     
  • FTSE

    8,424.20
    +3.94 (+0.05%)
     
  • Dow Jones

    39,806.77
    -196.82 (-0.49%)
     
  • DAX

    18,768.96
    +64.54 (+0.35%)
     
  • Hang Seng

    19,295.38
    -340.84 (-1.74%)
     
  • NIKKEI 225

    39,027.62
    -42.06 (-0.11%)
     

We Ran A Stock Scan For Earnings Growth And BioNTech (NASDAQ:BNTX) Passed With Ease

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.

In contrast to all that, many investors prefer to focus on companies like BioNTech (NASDAQ:BNTX), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide BioNTech with the means to add long-term value to shareholders.

See our latest analysis for BioNTech

BioNTech's Improving Profits

BioNTech has undergone a massive growth in earnings per share over the last three years. So much so that this three year growth rate wouldn't be a fair assessment of the company's future. As a result, we'll zoom in on growth over the last year, instead. BioNTech's EPS shot up from €30.76 to €42.47; a result that's bound to keep shareholders happy. That's a fantastic gain of 38%.

ADVERTISEMENT

It's often helpful to take a look at earnings before interest and tax (EBIT) margins, as well as revenue growth, to get another take on the quality of the company's growth. While BioNTech did well to grow revenue over the last year, EBIT margins were dampened at the same time. So if EBIT margins can stabilize, this top-line growth should pay off for shareholders.

In the chart below, you can see how the company has grown earnings and revenue, over time. For finer detail, click on the image.

earnings-and-revenue-history
earnings-and-revenue-history

Of course the knack is to find stocks that have their best days in the future, not in the past. You could base your opinion on past performance, of course, but you may also want to check this interactive graph of professional analyst EPS forecasts for BioNTech.

Are BioNTech Insiders Aligned With All Shareholders?

Owing to the size of BioNTech, we wouldn't expect insiders to hold a significant proportion of the company. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. Notably, they have an enviable stake in the company, worth €5.9b. Coming in at 19% of the business, that holding gives insiders a lot of influence, and plenty of reason to generate value for shareholders. Very encouraging.

Should You Add BioNTech To Your Watchlist?

You can't deny that BioNTech has grown its earnings per share at a very impressive rate. That's attractive. With EPS growth rates like that, it's hardly surprising to see company higher-ups place confidence in the company through continuing to hold a significant investment. Fast growth and confident insiders should be enough to warrant further research, so it would seem that it's a good stock to follow. You should always think about risks though. Case in point, we've spotted 1 warning sign for BioNTech you should be aware of.

There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here